This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Pathogenesis

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Rheumatoid arthritis (RA) is an autoimmune disease which is probably initiated by plasma cells in the subsynovial layer of joints which secrete immunoglobulins (mainly IgG and IgM). The latter bind with native IgG and activate complement. Complement activation stimulates leucocyte proliferation and activation.

There may also be a synchronous activation of immune pathways: one of the first histological signs of RA is the infiltration of the synovium with T cells. The T cells may become organised into aggregates. Genetic linkage with HLA-DR genes suggests that the pathogenetic defect may be at the level of antigen presentation, in the context of MHC class II, to T cells.

T cells release cytokines including:

  • tumour necrosis factor alpha
  • interleukin 1

These cytokines may stimulate:

  • synovium to become locally invasive (pannus) with destruction of periarticular soft tissues, articular cartilage and bone
  • angiogenesis and the formation of high endothelial venules which accelerate cell infiltration
  • secretion of inflammatory mediators and metalloproteinases by synoviocytes

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.